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No post‑operative complications such as scar 
contracture, graft failure or relapse of disease were 
encountered. With regard to hemostasis, high flow 
vessels greater than 500 µm are likely to bleed after 
carbon dioxide laser whereas without blood flow, 
vessels up to 2 mm have been coagulated.[3] An 
additional advantage of using carbon dioxide laser in 
defocused mode may be the destruction of residual 
lesions by the heat generated during the procedure.
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Electrochemotherapy for a locally 
advanced basal cell carcinoma 
on the forehead
Sir,
Electrochemotherapy (ECT) is an effective loco‑regional 
therapy for solid skin cancers with a high overall 
objective response rate and good cosmetic results. It is 
used for the treatment of cutaneous and subcutaneous 
tumour nodules where standard treatments have failed 
or proved to be inappropriate. It is mainly indicated 
in melanoma, Kaposi sarcoma, and cutaneous or 
subcutaneous metastases. Recent studies have focused 
on its role in the treatment of cutaneous tumours, in 
particular basal cell carcinoma (BCC) and squamous 
cell carcinoma of the head and neck.[1,2]
This therapeutic modality is based on the combination 
of electroporation and the administration of cytotoxic 
low permeability drugs. Electroporation uses pulsed, 
high‑intensity electric fields to temporarily increase cell 
membrane permeability by creation of pores, thereby 
allowing non‑permeable chemotherapeutic agents to 
enter the cells. These electric pulses also increase the 
cytotoxicity of the drugs. Bleomycin and cisplatin are 
the two commonly used drugs in this method.[3] The 
clinical procedures for a standardized, efficient and 
safe electric pulse and drug administration protocol 
for electrochemotherapy are provided by the results of 
a multicenter European Standard Operating Procedure 
of Electrochemotherapy (ESOPE).[4] We report our 
experience in a case of basal cell carcinoma.
A 54‑year‑old man presented with a pigmented and 
deep infiltrating plaque localized over the forehead. 
The lesion represented a relapsed basal cell carcinoma 
confirmed by histopathology [Figure 1a and b]. He 
was operated with Moh’s surgical technique one 
year earlier, but the lesion relapsed at the same 
site [Figure 2a]. We offered electrochemotherapy as a 
treatment option as he refused surgical intervention. 
A bolus of bleomycin and an electrical pulse generator 
was used under general anesthesia following the 
ESOPE guidelines. Bleomycin was administered 
intravenously in a dosage of 30000 IU followed by the 
application of electric pulses directly over the tumour. 
We used a linear field of 20 mm and the median time 
of treatment was 30 minutes. The procedure was 
Figure 5: Left axilla, 12 months following surgery and grafting 
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well tolerated and led to a rapid clinical regression 
of the lesion. At one year of follow up, mild scarring 
with hyperpigmentation was seen over the treated 
site [Figure 2b]. There was no evidence of relapse on 
histopathological and dermoscopic examination.
Basal cell carcinoma is the most common cutaneous 
malignant neoplasm, accounting for up to 80% of non 
melanoma skin cancers and has an estimated annual 
incidence of 0.1 to 0.5% in the United States. Surgery 
is the standard treatment but in some cases there could 
be a progression or relapse of the disease. Treatment 
must be individualized according to the patient and 
depends upon the location, size, tumour sub‑type, 
patient preferences and on the cost effectiveness of 
therapy. Due to the location, there was a risk of facial 
nerve damage during surgery. Biological therapies 
such as epidermal growth factor receptor or Hedgehog 
inhibitor are costly[5]. Electrochemotherapy is a 
low risk therapeutic option with good clinical and 
aesthetic results. Its use in locally advanced basal 
cell carcinoma has not been standardized yet. It 
has been reported that electrochemotherapy with 
bleomycin sulphate gave the best response rates in 
basal cell carcinoma among a variety of primary and 
secondary skin tumours with a complete response in 
up to 94.4% of cases after one treatment session.[5]
Potential contraindications to this technique include 
poor renal function, arrhythmia, pacemaker use and 
pulmonary fibrosis. A number of studies have shown 
that electrochemotherapy is associated with a good 
overall response rate. Gargiulo et al.,[2] reported no 
recurrences during a mean follow‑up of 20 months 
in a non‑randomised study of 34 patients including 
20 patients with BCC, and improved local tumour control 
with repeated electrochemotherapy. The only side effects 
reported are mild and transient erythema and oedema 
which resolve within 24 hours. In peculiar locations 
such as the orbit or eye muscles, electrochemotherapy 
does not cause significant dysfunctional outcome. 
A septal cartilage perforation was reported in 1 patient 
receiving treatment in the right nasal vestibule.[2]
Therapeutic response occurs without any increased 
morbidity for the patient with tissue‑sparing and low 
risk due to the minimal dose of chemotherapy, local 
anaesthesia, absence of surgical wounds, good aesthetic 
results, brief hospitalization and high compliance of 
the patient. Furthermore, the absence of systemic side 
effects and low immunosuppression even with repeated 
doses make this a suitable technique for elderly 
Figure 1: (a) Basal cell carcinoma (H and E, ×40). (b) Infiltrative 
growth of basal cell carcinoma (H and E, ×40)
ba
Figure 2: (a) A deep, infiltrating plaque localized over the forehead. 
(b) Post-electrochemotherapy, at one year follow up, with mild 
scarring and hyperpigmentation
ba
patients with poor general condition or co‑morbidities. 
In conclusion, this technique appears to be well 
tolerated, safe and repeatable. In our case, this approach 
gave very satisfying results with no recurrence and a 
good aesthetic outcome at follow up one year later. Our 
experience, along with that of others, demonstrates that 
electrochemotherapy with intravenous or intra‑tumour 
bleomycin is an effective treatment option for patients 
with advanced basal cell carcinoma.
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